title: LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma.
abstract: BACKGROUND
  Leishmaniasis, a fatal parasitic disease, is the second largest parasitic killer in the world and miltefosine is the first and only oral drug available for its treatment.
  
  
  RESULTS
  A rapid, sensitive and simple LC-MS/MS method for miltefosine quantification in hamster and human plasma was developed and validated over the range of 2.5-400 ng/ml. The mass spectrometric detection of the drug was carried out in multiple reaction monitoring mode (m/z 408.1→125.1) using an electrospray positive ionization. The protein precipitation method was employed for sample (50 µl) cleanup.
  
  
  CONCLUSIONS
  The proposed method provided accurate and precise high-throughput quantification of miltefosine in plasma and was successfully applied to its oral PK study in Golden Syrian hamsters.
authors.affiliation: Pharmacokinetics & Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.|Academy of Scientific & Innovative Research, New Delhi, India.
authors.forename: Swati
authors.initials: S
authors.lastname: Jaiswal
authors.affiliation: Pharmacokinetics & Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.|Academy of Scientific & Innovative Research, New Delhi, India.|Department of Pharmaceutics & Drug Delivery, The University of Mississippi, MS 38677, USA.
authors.forename: Abhisheak
authors.initials: A
authors.lastname: Sharma
authors.affiliation: Pharmacokinetics & Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.|Academy of Scientific & Innovative Research, New Delhi, India.
authors.forename: Mahendra
authors.initials: M
authors.lastname: Shukla
authors.affiliation: Pharmacokinetics & Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.|Academy of Scientific & Innovative Research, New Delhi, India.
authors.forename: Jawahar
authors.initials: J
authors.lastname: Lal
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000818:Animals; D000981:Antiprotozoal Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid / Q000592:standards; D006224:Cricetinae; D006207:Half-Life; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy; D057230:Limit of Detection; D008297:Male; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D012015:Reference Standards; D021241:Spectrometry, Mass, Electrospray Ionization / Q000592:standards
chemical_list: D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine
keywords: HPLC–MS/MS; leishmaniasis; miltefosine